SP 0218
Alternative Names: SP-0218; vYF - Sanofi; Yellow fever vaccine - SanofiLatest Information Update: 08 Jun 2025
At a glance
- Originator Sanofi Pasteur
- Developer Sanofi
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Yellow fever
Most Recent Events
- 22 May 2025 Phase-III clinical trials in Yellow fever (Prevention) in USA (SC) (NCT07002060)
- 27 Apr 2024 Immunogenicity and adverse events data from phasw IIb trial in Yellow fever presented at the 34th Congress of the European Society of Clinical Microbiology and Infectious (ESCMID-2024)
- 19 Feb 2024 Sanofi announces intention to submit an application to the regulatory body for Yellow fever (Prevention) (SC), in 2026 or beyond (Sanofi pipeline, February 2024)